Generalized prurigo nodularis is a severe and widespread morphologic manifestation of chronic pruritus.1 This condition is challenging to treat and results in a high burden of disease.1 We examined the effectiveness of the interleukin (IL) 4 receptor α inhibitor dupilumab as a novel treatment option for generalized prurigo nodularis.